OH....how quickly they forget.......................................................................................kiddin !
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that in a preclinical study of Inovio's SynCon® DNA vaccine against Ebola and Marburg filoviruses, labeled "Category A" bioterrorism agents by the U.S. government, the vaccine induced strong and broad immune responses and demonstrated 100% protection against death following a challenge with multiple variants of the pathogen in two animal models.
There is no approved vaccine or therapy available against these highly virulent pathogens that have killed up to 90% of the people they infected. Because these viruses could potentially be easily transmitted, result in high mortality rates and cause a major public health impact, various agencies are seeking solutions for public health preparedness. A DNA vaccine could offer faster design and manufacturing timelines than traditional vaccine approaches, but particularly important, Inovio's SynCon® products offer the potentially preemptive advantage of enabling a design to provide broad protection encompassing multiple families of these so-called filoviruses.
Preclinical data was published in the peer-reviewed journal Molecular Therapy in a paper, "Induction of Broad Cytotoxic T Cells by Protective DNA Vaccination Against Marburg and Ebola," authored by Inovio researchers and collaborators.
Using Inovio's proprietary SynCon® design approach, Inovio researchers developed a polyvalent DNA vaccine consisting of three consensus plasmids to broadly target variant virus strains within three distinct families of Ebola and Marburg viruses. In the first part of this study, following two vaccinations using Inovio's proprietary CELLECTRA® electroporation device, 100% of vaccinated guinea pigs were protected from death following a virus challenge. The researchers observed significant increases in neutralizing antibody titers and strong and broad levels of vaccine-induced T-cells, including "killer" T-cells, and subsequently conducted a test in mice using only one vaccination – this single dose also fully protected the animals from death following a virus challenge. In addition, unlike the non-vaccinated animals, vaccinated animals were protected from weight loss.
Dr. Joseph Kim, Inovio's President and CEO said, "This study again demonstrates the preventive potency and broad immune response that we consistently see in studies of our DNA portfolio of vaccines. These immune response characteristics are the type considered necessary to achieve protection in humans. These outstanding results support Inovio's active biodefense program, which has garnered multiple grants from the Department of Defense, Defense Threat Reduction Agency (DTRA), National Institute of Allergy and Infectious Diseases (NIAID), and other government agencies focused on public health which value our DNA vaccine approach to treating and preventing disease."
Sentiment: Strong Buy
Tuesday, August 5, 2014 at 10:00 a.m. EST
Access to Teleconference:
Dial (201) 689-8562
A telephonic replay will be available from 1:00 pm EST the day of the call until Tuesday, August 12, 2014. To listen to the archived call, dial (858) 384-5517 and enter conference ID number 13587622.
Yahoo has yanked all the truth about this article that has been posted..What do you think about someone monitoring your thoughts..sreering the way you think..signed...George Orwell..Your only told what they want you to be told..
funny how some people respond ,no factual argument in shoring up a position they mite take.They go for the throat, and that's enough. It seems the better the news, the lower we go .The R/S was a partial kiss of poison. spread on stock value across the board...
OH..!! I thought you were going to say,"hunt them down and cut their heads off.."....siddin' shorts...sleep well..
Thank you very much for replying..6 hrs on this..google should have a patch..this is nuts..I'm going to have to leave chrome behind as will others if we don't get any support..
any one got an Idea..I followed goog instructions but didn't work will be a big problem if goog doesn't step in.